355 related articles for article (PubMed ID: 24738991)
21. Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism.
Mrozinska S; Cieslik J; Broniatowska E; Malinowski KP; Undas A
J Thromb Haemost; 2019 Nov; 17(11):1912-1922. PubMed ID: 31323706
[TBL] [Abstract][Full Text] [Related]
22. A prothrombotic state and denser clot formation in patients following acute limb ischemia of unknown cause.
Karpińska IA; Nowakowski T; Wypasek E; Plens K; Undas A
Thromb Res; 2020 Mar; 187():32-38. PubMed ID: 31951936
[TBL] [Abstract][Full Text] [Related]
23. Altered fibrin clot properties in patients with chronic heart failure and sinus rhythm: a novel prothrombotic mechanism.
Palka I; Nessler J; Nessler B; Piwowarska W; Tracz W; Undas A
Heart; 2010 Jul; 96(14):1114-8. PubMed ID: 20610458
[TBL] [Abstract][Full Text] [Related]
24. Altered plasma fibrin clot properties in essential thrombocythemia.
Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
[TBL] [Abstract][Full Text] [Related]
25. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
26. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment.
Undas A; Kaczmarek P; Sladek K; Stepien E; Skucha W; Rzeszutko M; Gorkiewicz-Kot I; Tracz W
Thromb Haemost; 2009 Dec; 102(6):1176-82. PubMed ID: 19967149
[TBL] [Abstract][Full Text] [Related]
27. Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk.
Gajos G; Konieczynska M; Zalewski J; Undas A
Cardiovasc Diabetol; 2015 May; 14():44. PubMed ID: 25928628
[TBL] [Abstract][Full Text] [Related]
28. Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
Janion-Sadowska A; Natorska J; Siudut J; Ząbczyk M; Stanisz A; Undas A
Thromb Haemost; 2017 Aug; 117(9):1739-1749. PubMed ID: 28771277
[TBL] [Abstract][Full Text] [Related]
29. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans.
Undas A; Nowakowski T; Cieśla-Dul M; Sadowski J
Atherosclerosis; 2011 Apr; 215(2):481-6. PubMed ID: 21324459
[TBL] [Abstract][Full Text] [Related]
30. Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking.
Ząbczyk M; Królczyk G; Czyżewicz G; Plens K; Prior S; Butenas S; Undas A
Med Oncol; 2019 Mar; 36(4):37. PubMed ID: 30891644
[TBL] [Abstract][Full Text] [Related]
31. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
32. Altered fibrin clot properties in patients with premature peripheral artery disease.
Okraska-Bylica A; Wilkosz T; Słowik L; Bazanek M; Konieczyńska M; Undas A
Pol Arch Med Wewn; 2012; 122(12):608-15. PubMed ID: 23235487
[TBL] [Abstract][Full Text] [Related]
33. Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?
Bouma BN; Mosnier LO
Ann Med; 2006; 38(6):378-88. PubMed ID: 17008302
[TBL] [Abstract][Full Text] [Related]
34. Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study.
Cieslik J; Mrozinska S; Broniatowska E; Undas A
Blood; 2018 Feb; 131(7):797-807. PubMed ID: 29242187
[TBL] [Abstract][Full Text] [Related]
35. Prothrombotic clot properties can predict venous ulcers in patients following deep vein thrombosis: a cohort study.
Polak MW; Siudut J; Plens K; Undas A
J Thromb Thrombolysis; 2019 Nov; 48(4):603-609. PubMed ID: 31432450
[TBL] [Abstract][Full Text] [Related]
36. Antithrombin Deficiency Is Associated with Prothrombotic Plasma Fibrin Clot Phenotype.
Natorska J; Corral J; de la Morena-Barrio ME; Bravo-Pérez C; Bagoly Z; Bereczky Z; Treliński J; Witkowski M; Klajmon A; Undas A; Ząbczyk M
Thromb Haemost; 2023 Sep; 123(9):880-891. PubMed ID: 37201530
[TBL] [Abstract][Full Text] [Related]
37. Plasma fibrin clot proteomics in patients with acute pulmonary embolism: Association with clot properties.
Bryk AH; Natorska J; Ząbczyk M; Zettl K; Wiśniewski JR; Undas A
J Proteomics; 2020 Oct; 229():103946. PubMed ID: 32810596
[TBL] [Abstract][Full Text] [Related]
38. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress.
Undas A; Szułdrzynski K; Stepien E; Zalewski J; Godlewski J; Tracz W; Pasowicz M; Zmudka K
Atherosclerosis; 2008 Feb; 196(2):551-7. PubMed ID: 17640649
[TBL] [Abstract][Full Text] [Related]
39. Plasma fibrin clot properties and cardiovascular mortality in patients with type 2 diabetes: a long-term follow-up study.
Bryk AH; Konieczyńska M; Polak M; Plicner D; Bochenek M; Undas A
Cardiovasc Diabetol; 2021 Feb; 20(1):47. PubMed ID: 33602240
[TBL] [Abstract][Full Text] [Related]
40. Altered plasma fibrin clot properties in hypertensive patients with obstructive sleep apnoea are improved by continuous positive airway pressure treatment.
Jóźwik-Plebanek K; Prejbisz A; Wypasek E; Pręgowska-Chwała B; Hanus K; Kaszuba AM; Januszewicz M; Bieleń P; Kabat M; Kruk M; Dobrowolski P; Klisiewicz A; Śliwiński P; Januszewicz A; Undas A
J Hypertens; 2017 May; 35(5):1035-1043. PubMed ID: 28141659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
